Johnson Investment Counsel’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$263K Sell
1,216
-30
-2% -$5.74K ﹤0.01% 765
2026
Q1
$228K Sell
1,246
-23
-2% -$4.24K ﹤0.01% 769
2025
Q4
$223K Sell
1,269
-160
-11% -$26.1K ﹤0.01% 748
2025
Q3
$200K Buy
+1,429
New +$193K ﹤0.01% 805
2025
Q2
Sell
-1,513
Closed -$207K 822
2025
Q1
$207K Sell
1,513
-166
-10% -$23.7K ﹤0.01% 756
2024
Q4
$257K Sell
1,679
-386
-19% -$65.1K ﹤0.01% 691
2024
Q3
$400K Buy
2,065
+100
+5% +$20.9K ﹤0.01% 558
2024
Q2
$456K Sell
1,965
-90
-4% -$19.6K ﹤0.01% 512
2024
Q1
$443K Hold
2,055
﹤0.01% 528
2023
Q4
$532K Buy
2,055
+144
+8% +$35.4K 0.01% 472
2023
Q3
$491K Sell
1,911
-19
-1% -$5.08K 0.01% 469
2023
Q2
$550K Sell
1,930
-235
-11% -$70K 0.01% 446
2023
Q1
$602K Sell
2,165
-15
-0.7% -$4.15K 0.01% 428
2022
Q4
$604K Buy
2,180
+31
+1% +$8.76K 0.01% 426
2022
Q3
$574K Sell
2,149
-72
-3% -$15.3K 0.01% 412
2022
Q2
$453K Buy
2,221
+190
+9% +$38.8K 0.01% 466
2022
Q1
$428K Buy
2,031
+5
+0.2% +$1.09K 0.01% 504
2021
Q4
$486K Sell
2,026
-7
-0.3% -$1.8K 0.01% 475
2021
Q3
$575K Sell
2,033
-30
-1% -$9.83K 0.01% 419
2021
Q2
$714K Sell
2,063
-47
-2% -$14.2K 0.01% 378
2021
Q1
$590K Sell
2,110
-1,178
-36% -$318K 0.01% 391
2020
Q4
$805K Sell
3,288
-164
-5% -$42.3K 0.01% 339
2020
Q3
$979K Sell
3,452
-33
-0.9% -$9.2K 0.02% 286
2020
Q2
$932K Sell
3,485
-46
-1% -$13.8K 0.02% 293
2020
Q1
$1.12M Sell
3,531
-588
-14% -$178K 0.02% 229
2019
Q4
$1.22M Sell
4,119
-191
-4% -$53K 0.02% 273
2019
Q3
$1M Sell
4,310
-816
-16% -$190K 0.02% 306
2019
Q2
$1.2M Sell
5,126
-39
-0.8% -$9.01K 0.02% 271
2019
Q1
$1.22M Sell
5,165
-1,435
-22% -$452K 0.03% 280
2018
Q4
$1.99M Sell
6,600
-488
-7% -$156K 0.05% 192
2018
Q3
$2.5M Sell
7,088
-11,013
-61% -$3.79M 0.06% 183
2018
Q2
$5.25M Sell
18,101
-770
-4% -$216K 0.13% 114
2018
Q1
$5.17M Sell
18,871
-3,810
-17% -$1.18M 0.13% 109
2017
Q4
$7.22M Sell
22,681
-2,255
-9% -$723K 0.18% 96
2017
Q3
$7.81M Buy
24,936
+428
+2% +$127K 0.21% 86
2017
Q2
$6.65M Sell
24,508
-1,253
-5% -$331K 0.19% 93
2017
Q1
$7.04M Sell
25,761
-604
-2% -$171K 0.2% 90
2016
Q4
$7.48M Sell
26,365
-4,076
-13% -$1.21M 0.23% 84
2016
Q3
$9.53M Sell
30,441
-2,850
-9% -$844K 0.3% 75
2016
Q2
$8.05M Buy
33,291
+239
+0.7% +$63K 0.27% 83
2016
Q1
$8.6M Buy
33,052
+697
+2% +$184K 0.3% 68
2015
Q4
$9.91M Sell
32,355
-4,055
-11% -$1.17M 0.35% 64
2015
Q3
$10.6M Buy
36,410
+5,048
+16% +$1.67M 0.39% 61
2015
Q2
$12.7M Buy
31,362
+10,944
+54% +$4.39M 0.43% 61
2015
Q1
$8.62M Buy
20,418
+18,672
+1,069% +$7.36M 0.29% 78
2014
Q4
$593K Sell
1,746
-3
-0.2% -$971 0.02% 284
2014
Q3
$578K Sell
1,749
-352
-17% -$116K 0.02% 291
2014
Q2
$662K Buy
2,101
+55
+3% +$16.6K 0.02% 239
2014
Q1
$625K Sell
2,046
-71
-3% -$22.5K 0.02% 239
2013
Q4
$591K Sell
2,117
-15
-0.7% -$3.88K 0.02% 250
2013
Q3
$513K Sell
2,132
-140
-6% -$31.3K 0.02% 253
2013
Q2
$488K Buy
+2,272
New +$485K 0.02% 253

Other funds holding BIIB

Johnson Investment Counsel's BIIB Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Biogen (BIIB) stake by 2.4% in Q2 2026, selling an estimated $5.74K and leaving 1,216 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Johnson Investment Counsel first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.7M in Q2 2015. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Johnson Investment Counsel held 1,216 shares of Biogen worth $263K as of Q2 2026.
  • Johnson Investment Counsel sold 30 Biogen shares in Q2 2026, an estimated $5.74K.
  • Biogen made up ﹤0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #765 holding.
  • Johnson Investment Counsel first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Johnson Investment Counsel's Biogen position peaked at $12.7M in Q2 2015.
  • 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.